The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

A recent research highlights the potential of psilocybin as a groundbreaking treatment for moderate to severe major ...

Pediatric patients are also more susceptible to becoming addicted to ketamine and forming substance abuse disorders.

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with ...

The AMPLIFY trial will assess the safety and efficacy of ABX-002 when used alongside existing SSRI or SNRI treatments.

A study comparing psilocybin to the SSRI escitalopram found both drugs improved depressive symptoms similarly over six months ...

SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants like escitalopram improve mood and cognitive functions by ...

For patients with major depressive disorder (MDD), seizure duration of 60 to 69 seconds induced by electroconvulsive therapy (ECT) is associated with the highest remission rates compared with ...